All Updates

All Updates

icon
Filter
Funding
Gilgamesh Pharmaceuticals raises USD 39 million Series B
Psychedelic Medicine
Dec 15, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Dec 15, 2022

Gilgamesh Pharmaceuticals raises USD 39 million Series B

Funding

  • New York-based psychedelic biotechnology company Gilgamesh Pharmaceuticals raised USD 39 million in a Series B funding round led by Prime Movers Lab with participation from Alumni Ventures, Palo Santo, and Negev Capital, among others.

  • The funding will be used to initiate Phase I/Ib safety and efficacy studies for the company’s lead programs GM-1020 and GM-2505 which are reportedly faster and less hallucinogenic compared to other psychedelic drugs being developed.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.